8-K - Corcept Therapeutics Incorporated | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Corcept Therapeutics Incorporated announced on March 25, 2026, that the U.S. Food and Drug Administration approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received one to three prior systemic treatment regimens, at least one including bevacizumab. Approval based on ROSELLA trial demonstrating 35% reduction in death risk and 30% reduction in progression risk.

Key Takeaways

1FDA approved Lifyorli™ (relacorilant) + nab-paclitaxel on March 25, 2026

2Indication: platinum-resistant ovarian/fallopian tube/primary peritoneal cancer, 1-3 prior regimens including bevacizumab

3ROSELLA trial: 381 patients, 1:1 randomization, no biomarker required

4Overall survival: 16.0 months vs 11.9 months (HR 0.65, p=0.0004)

5PFS by BICR: HR 0.70, p=0.008

6First FDA-approved selective glucocorticoid receptor antagonist (SGRA)

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

. Other Events. On March 25, 2026, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has approved L

Other Event

9.01

. Financial Statements and Exhibits (d) Exhibits Exhibits No. Description 99.1 Press Release of Corcept Therapeutics Incorporated, March 25, 2026. 104.1 Cover P

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1